Important: After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to www.mycme.com/obesity2 on any browser to complete the activity.
Description
In June 2021, the FDA approved a once-weekly, subcutaneous formulation of the GLP-1 receptor agonist semaglutide for chronic weight management in adults who are overweight or obese and have at least one weight-related comorbidity, making it the first new anti-obesity drug approved in the U.S. since 2014. While pharmacotherapy is an important tool for obesity management, these modalities must be appropriately used, based on the available evidence, established indications, and guidelines for therapeutic outcomes assessment.
In this audio activity, Dr. Pamela Kushner and Dr. Ken Fujioka discuss appropriate obesity treatment goals individualized to the needs of each patient and review the reasons that patients frequently regain weight lost via lifestyle interventions. The faculty take a closer look at the spectrum of available pharmacologic options for obesity treatment and discuss how some of these agents directly target the pathophysiology that underlies the disease, resulting in meaningful weight loss.
This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.
This activity is supported by an educational grant from Novo Nordisk.
At the conclusion of this activity, participants should be better able to:
Faculty
Pamela Kushner, MD, FAAFP
Clinical Professor
University of California at Irvine
Irvine, CA
Dr. Kushner is a consultant for Abbott, Intuity Medical, Inc., and Phathom Pharmaceuticals and is speaker and consultant for AstraZeneca, Eli Lilly and Company, GSK, and Janssen Pharmaceuticals, Inc.
Ken Fujioka, MD
Director Nutrition and Metabolic Research
Scripps Clinic
Division of Diabetes and Endocrine
San Diego, CA
Dr. Fujioka is a consultant for Novo Nordisk, Gelesis, Nalpropion Pharmaceuticals LLC, Amgen Inc., KVK Tech, Inc, Phenomix Sciences, LLC, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Rhythm Pharmaceuticals, Inc., and Takeda Pharmaceuticals. He is also on the speakers’ bureaus of Novo Nordisk, Nalpropion, Rhythm, and Takeda.
All of the relevant financial relationships listed for these individuals have been mitigated.